ライフサイエンスコーパス: mitral valve disease

1 ntional surgical approaches for degenerative mitral valve disease.

2 n selected patients with combined aortic and mitral valve disease.

3 al valve repair or from organ donors without mitral valve disease.

4 s for the treatment of aortic, pulmonic, and mitral valve disease.

5 n in part the pathophysiology of Fen-related mitral valve disease.

6 fibrillation, particularly in patients with mitral valve disease.

7 roaches for treatment of isolated aortic and mitral valve disease.

8 perhaps more common nonsyndromic variants of mitral valve disease.

9 o promote the development of AF in rheumatic mitral valve disease.

10 oronary artery disease (CAD) without primary mitral valve disease.

11 6.6%), ischemic (4.6%), and traumatic (0.3%) mitral valve disease.

12 n of atrial arrhythmias and in patients with mitral valve disease.

13 prove outcomes in patients with degenerative mitral valve disease.

14 the diagnosis and treatment of patients with mitral valve disease.

15 escribed the use of ultrasound for assessing mitral-valve disease.

16 with increased repair rates of degenerative mitral valve disease (adjusted odds ratio [OR]: 1.13 for

17 e cellular mechanisms involved in myxomatous mitral valve disease and calcific aortic valve disease a

18 on, the management of rheumatic, aortic, and mitral valve disease, and the application of balloon com

19 elopments in the management of patients with mitral valve disease are reviewed.

20 orifice area, prolapse height and volume in mitral valve disease, area of the left ventricular outfl

21 creased incidence of cardiovascular disease, mitral valve disease, arrhythmias, and mortality.

22 ater understanding of the pathophysiology of mitral valve disease as well as the improved outcome rel

23 preoperative differentiation of degenerative mitral valve disease based on etiology (predominantly Ba

24 t outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in pa

25 of mitral valve repair techniques to address mitral valve disease can be related to increased surgica

26 learly shown that patients with degenerative mitral valve disease can expect very durable repairs, an

27 Forty-nine patients with degenerative mitral valve disease classified as FED (n=31) and DMD (n

28 eration (DMD) are phenotypes of degenerative mitral valve disease defined morphologically.

29 The field of mitral valve disease diagnosis and management is rapidly

30 will surgeons, who have led the treatment of mitral valve disease for the past 30 years, have a role

31 aortic regurgitation and without associated mitral valve disease) from 3 different medical centers (

32 dramatic changes in the course of myxomatous mitral valve disease in both dogs and humans.

33 ial tissues from the patients with rheumatic mitral valve disease in either sinus rhythm or persisten

34 close to 60% of patients having surgery for mitral valve disease in the US.

35 The etiology of mitral valve disease is changing.

36 he value of robotically assisted surgery for mitral valve disease is questioned because the high cost

37 Because up to 6% of PSRA patients develop mitral valve disease, it is recommended that antistrepto

38 Patients with significant mitral valve disease (mitral stenosis or > or = moderate

39 Patients were divided into the mitral valve disease (MVD) category (ie, those with mitr

40 left atrial pressure (LAP) in patients with mitral valve disease (MVD), given the confounding effect

41 worsened in 65.4% of patients with intrinsic mitral valve disease (myxomatous, calcific, or ischemic

42 tic stenosis (n=20), arch obstruction (n=7), mitral valve disease (n=5), apical aortic conduit stenos

43 For patients with mitral valve disease, options for tissue valve replaceme

44 pid regurgitation, whether in the context of mitral valve disease or heart failure, should no longer

45 cant left-sided valve disease [predominantly mitral valve disease]), previous documented episodes of

46 ower the incidence of clinically significant mitral valve disease requires further study.

47 Therefore, patients with intrinsic mitral valve disease should be considered for concomitan

48 a repair, valve replacement for degenerative mitral valve disease should be infrequent.

49 AC, a risk factor for clinically significant mitral valve disease, suggesting a causal association.

50 also develop aortic root aneurism and aorto-mitral valve disease that can be fatal depending on the

51 timate goal of preventing the progression of mitral valve disease to the stage of clinical expression

52 Patients with intrinsic mitral valve disease were excluded.

53 t surgical approaches to treat patients with mitral valve disease who may also concurrently suffer fr

54 ents (median age 10 months) with symptomatic mitral valve disease who underwent placement of a supraa

55 Children with symptomatic mitral valve disease whose annulus is too small for the